Anti-Cathepsin G Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibody to human Cathepsin G (CTSG, EC 3.4.21.20), validated for Western blot.
Host
Rabbit, Polyclonal
Reactivity
Validated- Human Potential-Mouse, Pan, Monkey
UniProt
P08311
Size
100ug
Cat. #
RP2CathepsinG

In stock

SKU
RP-CathepsinG

Options

As low as: $130.00

Target Overview

Cathepsin G (CTSG, EC 3.4.21.20, UniProt P08311) is a serine protease stored in azurophilic granules of neutrophils and mast cells that exhibits both trypsin- and chymotrypsin-like specificity. The enzyme preferentially cleaves substrates after phenylalanine, tyrosine, tryptophan, and leucine residues with a preference for negatively charged amino acids in the P2' position. Beyond its proteolytic function, Cathepsin G displays antibacterial activity against both Gram-negative and Gram-positive bacteria independent of its catalytic activity. The protease plays documented roles in platelet activation through cleavage of the F2RL3/PAR4 receptor, immune cell recruitment and activation, and processing of complement C3. Cathepsin G also cleaves protease-activated receptor-1 (F2R/PAR1) and thrombomodulin, with cleavage site determining whether receptor activation or inhibition occurs. Substrates include vimentin, the synovial lubricant PRG4/lubricin, interleukin-36 gamma, and cortactin. Triple Point Biologics offers three rabbit polyclonal antibodies raised against the propeptide and amino-terminal region of the active enzyme, validated for detection of human Cathepsin G in Western blot, immunohistochemistry, and immunofluorescence applications.

Background

Cathepsin G is released from neutrophil azurophilic granules during degranulation and participates in both intracellular and extracellular proteolysis. The enzyme contributes to pathogen killing, extracellular matrix remodeling, and regulation of inflammatory signaling through selective cleavage of chemokines, cytokines, and cell-surface receptors. Recent work has implicated Cathepsin G in endothelial injury during neutrophil extravasation, where the protease degrades cortactin in the endothelial cytoskeleton to facilitate transendothelial migration. Guerrero-Fonseca et al. (2026) demonstrated that neutrophil serine proteases including Cathepsin G cleave cortactin at specific sites, promoting vascular permeability and leukocyte transmigration during inflammation. Cathepsin G has emerged as a biomarker and mechanistic contributor in multiple disease contexts. In myeloid leukemia, Cathepsin G associates with cerebral vascular injury and intracranial hemorrhage, potentially through disruption of endothelial integrity. The enzyme is also detected in synovial fluid during inflammatory joint diseases and osteoarthritis, where it cleaves the cartilage lubricant PRG4. Proteomic studies of knee osteoarthritis synovial fluid consistently identify Cathepsin G among dysregulated proteins. The enzyme is further implicated in neutrophil extracellular trap formation, with potential relevance to metabolic dysfunction-associated fatty liver disease and air pollutant-induced inflammation. Detection of Cathepsin G by Western blot and immunohistochemistry is widely used to characterize neutrophil degranulation, assess protease release in inflammatory conditions, and localize enzyme expression in tissue sections. The three rabbit polyclonal antibodies available from Triple Point Biologics recognize epitopes in the propeptide and amino-terminal region of the mature enzyme, suitable for detection of both pro- and active forms in human samples with predicted cross-reactivity to mouse, non-human primate, and porcine orthologs.

References

  1. Guerrero-Fonseca IM et al (2026) Neutrophil serine proteases degrade endothelial cortactin and promote extravasation. J Cell Biol. PubMed · 10.1083/jcb.202410019
  2. Gi T et al (2026) Cathepsin G is associated with cerebral vascular injury in myeloid leukemia: a pathologic insight into intracranial hemorrhage. Res Pract Thromb Haemost. PubMed · 10.1016/j.rpth.2026.103433
  3. Parrotta EI et al (2026) Synovial Fluid Proteomic Biomarkers in Knee Osteoarthritis: A Systematic Review and Gene Ontology Analysis. Cartilage. PubMed · 10.1177/19476035261446251
  4. Hou Y et al (2026) Identifying potential relationships between air pollutants and neutrophil extracellular traps formation in metabolic dysfunction-associated fatty liver disease by integrating computational toxicology and multi-omics data. Environ Pollut. PubMed · 10.1016/j.envpol.2026.128320

Additional Specifications

Gene Symbol CTSG
UniProt ID P08311
Host Species Rabbit
Species Reactivity Validated- Human
Potential-Mouse, Pan, Monkey
Pack Size 100ug
Immunogen (propeptide and amino end of active enzyme)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 19-20.
Immunogen (Catalytic domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 21-243.
Immunogen (carboxy end of the catalytic domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 203-243.
Alternate Names CTSG, CG, EC 3.4.21.20, Cathepsin G

Frequently Asked Questions

What molecular weight should I expect for Cathepsin G on a Western blot?

Cathepsin G migrates at approximately 26-29 kDa on reducing SDS-PAGE, corresponding to the mature, active protease form following signal peptide and activation dipeptide cleavage. The full-length preproprotein is 255 amino acids, but the secreted mature enzyme begins at residue 27. You may occasionally observe a band near 37 kDa representing the inactive proenzyme form in certain cell lysates or granule preparations. Neutrophil and mast cell lysates typically show predominantly the 26-29 kDa species. Note that Cathepsin G is heavily glycosylated, which can cause minor MW heterogeneity between samples.

What starting dilution should I use for Western blot with this antibody?

Start at 1:1000 dilution in blocking buffer for Western blot applications, as specified in our validation data. This dilution has been confirmed with human neutrophil lysates and provides clean signal with minimal background when using standard chemiluminescent detection. If working with samples of lower Cathepsin G abundance—such as differentiated myeloid cell lines or tissue homogenates—you may need to increase antibody concentration to 1:500. Conversely, purified enzyme or concentrated granule preparations may permit dilution to 1:2000. Always include a neutrophil lysate positive control for initial titration.

Will this antibody recognize Cathepsin G in mouse samples?

Cross-reactivity with mouse Cathepsin G is predicted but not yet validated in our laboratory. Human and mouse Cathepsin G share approximately 73% amino acid identity, with conservation highest in the catalytic domain. Researchers have reported successful detection of mouse Cathepsin G using antibodies raised against human epitopes, but signal intensity and specificity vary. We recommend validating with a characterized mouse neutrophil lysate and including appropriate knockout or depletion controls if working with mouse samples. Validated human reactivity remains the only species we confirm from primary data.

Does Cathepsin G run as a single band or should I expect multiple forms?

In neutrophil lysates, you typically observe a predominant band at 26-29 kDa representing mature Cathepsin G. Additional bands may appear depending on sample type and preparation. A higher MW band around 37 kDa corresponds to the proenzyme, more abundant in biosynthetically active cells or when protease inhibitors are present during lysis. Degradation products below 26 kDa occasionally appear if samples undergo freeze-thaw cycles or protracted handling. Cathepsin G also undergoes N-glycosylation, contributing to minor band heterogeneity. For cleanest results, lyse cells in the presence of broad-spectrum protease inhibitors and process samples promptly.

What positive and negative controls should I use when working with this Cathepsin G antibody?

Human peripheral blood neutrophils or differentiated HL-60 or PLB-985 cells serve as strong positive controls; Cathepsin G constitutes approximately 2-5% of total neutrophil protein. Mast cell lines (HMC-1, LAD2) also express Cathepsin G, though at lower levels. For negative controls, use lymphocyte lysates, fibroblasts, or epithelial cell lines that lack myeloid differentiation. Recombinant Cathepsin G provides an additional positive control and confirms expected MW. Pre-incubating antibody with blocking peptide—if available—offers a specificity control. Always include a no-primary-antibody lane to assess secondary antibody cross-reactivity in complex lysates.

Can this antibody detect Cathepsin G in immunohistochemistry or immunofluorescence?

Triple Point Biologics antibodies in the protease portfolio are validated for Western blot and immunohistochemistry applications. While we have not generated immunofluorescence data specifically for this Cathepsin G antibody, polyclonal rabbit antibodies in our catalog have been successfully used for IF by customers. For IHC, antigen retrieval is typically required; citrate buffer (pH 6.0) heat-induced epitope retrieval is a reasonable starting method for formalin-fixed paraffin-embedded tissue containing neutrophils or mast cells. Optimal dilutions for IHC generally range from 1:100 to 1:500, though titration against your specific tissue type is necessary.

How should I store this antibody and what is the expected stability?

Store the antibody at -20°C in working aliquots to avoid repeated freeze-thaw cycles, which can reduce titer and increase aggregation. The antibody is supplied at 1 mg/mL in PBS with carrier protein and preservative. Under these conditions, stability typically exceeds two years at -20°C. For frequent use, prepare small aliquots (10-20 µL) to minimize freeze-thaw exposure, or maintain a working dilution at 4°C with 0.02% sodium azide for up to one month. Avoid prolonged storage in frost-free freezers due to temperature cycling. Centrifuge briefly before use if any precipitate forms.

What sample preparation considerations are important for detecting Cathepsin G?

Cathepsin G is a serine protease with both auto-catalytic and trans-proteolytic activity, so include protease inhibitors (PMSF, aprotinin, or a cocktail containing serine protease inhibitors) during cell lysis. Neutrophils and mast cells contain abundant proteases that remain active post-lysis and can degrade both Cathepsin G and other proteins. Use fresh lysates when possible; if freezing is necessary, snap-freeze in liquid nitrogen and store at -80°C. RIPA or standard NP-40 lysis buffers work well. Avoid boiling samples excessively, as Cathepsin G can aggregate. Reducing conditions are standard; DTT or β-mercaptoethanol at typical concentrations are appropriate.

Western blot validation for RP-CathepsinG — 3 panels across the domain-specific antibody variants. Each blot below shows the clone that validates a specific domain of the target protein.

Cathepsin-G: propeptide and amino end of active enzyme — WB validation
WB · Panel 1 Cathepsin-G: propeptide and amino end of active enzyme
Cathepsin-G: Catalytic domain — WB validation
WB · Panel 2 Cathepsin-G: Catalytic domain
Cathepsin-G: carboxy end of the catalytic domain — WB validation
WB · Panel 3 Cathepsin-G: carboxy end of the catalytic domain

Custom validation studies available on request — contact us.

Also known as:

  • CTSG
  • CG
  • EC 3.4.21.20
  • Cathepsin G
  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →